Figure 3.

Sensitivity of epidermal growth factor receptor (EGFR) with single or double uncommon mutations to EGFR‐tyrosine kinase inhibitors. A, C, HEK293 cells expressing G719A, G719S, L861Q, G719A/L861Q or G719S/L861Q mutant forms of yellow fluorescent protein‐EGFR‐intracellular domain were exposed to erlotinib (A) or afatinib (C) at the indicated concentrations for 6 h and then examined by fluorescence microscopy. Scale bars, 10 μm. B, D, Proportion of cells with fibril‐like structures for cells exposed to erlotinib (B) or afatinib (D) as in (A) and (C), respectively